L-arginine inhalation - PARI

Drug Profile

L-arginine inhalation - PARI

Latest Information Update: 12 Apr 2007

Price : $50

At a glance

  • Originator PARI
  • Class Basic amino acids; Diamino amino acids; Essential amino acids
  • Mechanism of Action Nitric oxide synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Clinical Phase Unknown Cystic fibrosis

Most Recent Events

  • 01 Dec 2006 Clinical trials in Cystic fibrosis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top